JZJ(SH:605266)2023-10-27 16:00Financial Performance - The company's operating revenue for Q3 2023 reached CNY 2,161,860,512, representing a year-on-year increase of 38.03%[5]. - Net profit attributable to shareholders for Q3 2023 was CNY 120,347,103, a growth of 13.94% compared to the same period last year[6]. - The net profit attributable to shareholders for the first nine months of 2023 increased by 42.03% year-on-year[10]. - The basic earnings per share for Q3 2023 was CNY 0.93, reflecting a growth of 13.41% compared to the previous year[10]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, increased by 11.69% in Q3 2023, reflecting the company's effective management strategies despite rising costs[17]. - The company's net profit for Q3 2023 reached CNY 277.35 million, a 42.37% increase compared to CNY 194.80 million in the same period last year[30]. - The company's net profit for the first nine months of 2023 was ¥278,437,907.10, representing a growth of ¥82,394,701.47 or 42.03% year-over-year[26]. - The company's net profit for Q3 2023 was CNY 277,351,113.08, an increase of 42.3% compared to CNY 194,803,984.81 in Q3 2022[76]. Revenue Growth - Online business revenue grew by 67.92% year-on-year, contributing to the overall revenue increase[8]. - In Q3 2023, the company's revenue reached 2,161,860,512, representing a year-over-year increase of 26.9% compared to Q3 2022's 1,702,769,381[12]. - The company achieved a total revenue of 6,499,586,188.65 yuan in the first nine months of 2023, with a gross margin of 35.88%, a decrease of 0.68% compared to the previous year[46]. - The company's revenue for the first nine months of 2023 increased by 38.03% compared to the same period last year, driven by a 47.91% growth in prescription and over-the-counter drug sales[49]. - Total revenue from sales of goods and services amounted to CNY 6.85 billion, reflecting a 47.28% growth from CNY 4.65 billion year-on-year[30]. - Total operating revenue for the first three quarters of 2023 reached ¥6,499,586,188.65, an increase of 38.0% compared to ¥4,708,961,386.37 in the same period of 2022[75]. Store Expansion - The number of stores increased by 18.28% year-on-year, with a net addition of 728 stores, bringing the total to a significant expansion[8]. - The company achieved a net increase of 656 stores in the first nine months of 2023, reaching a total of 4,711 stores, representing a growth of 16.18% compared to the beginning of the year[38]. - The company closed 8 stores due to strategic adjustments, while acquiring 61 stores during the same period[38]. - The company’s total pharmacy store count in the Hebei and Liaoning regions increased by 22.64%, with a net addition of 141 stores, totaling 818 stores[37]. - The company’s total pharmacy store count in the Sichuan region increased by 42.16%, with a net addition of 78 stores, totaling 263 stores[39]. - The company’s total pharmacy store count in the Chongqing region increased by 21.52%, with a net addition of 68 stores, totaling 384 stores[39]. - The company’s total pharmacy store count in the Guangxi region increased by 24.08%, with a net addition of 46 stores, totaling 237 stores[39]. Cost and Expenses - The gross profit margin decreased by 0.68% to 35.88%, but the gross profit amount increased by 35.46%[8]. - The company experienced a 30.46% increase in operating expenses in Q3 2023, attributed to the expansion of store locations and operational costs[17]. - The company's operating costs increased to ¥4,167,760,250.11, reflecting a rise of ¥1,180,214,949.95 or 39.50% due to higher revenue[28]. - Sales expenses for the period amounted to ¥1,713,623,486.46, an increase of ¥440,323,060.99 or 34.58%, driven by rising operational costs and online business growth[28]. Strategic Initiatives - The company implemented a strategy of "self-built + acquisition," successfully integrating the acquisition of 667 stores in the Hebei and Liaoning regions[8]. - The company aims to enhance its market presence in the Southwest and Jiliao regions, focusing on the integration of the Liaoning area and expanding into key national target regions[15]. - The company plans to strengthen its product category planning and enhance promotional efforts in collaboration with industrial enterprises to improve customer service and increase transaction frequency[16]. - The company is committed to improving its supply chain efficiency and service capabilities to better serve pharmaceutical industrial enterprises in the increasingly important outpatient market[16]. - The company is focusing on enhancing its operational efficiency and managing costs effectively to sustain profitability amid market fluctuations[30]. - The company is committed to digital transformation and improving its information systems to support regulatory requirements and service demands[65]. Market Trends and Challenges - The company is responding to market trends by emphasizing high cost-performance products and enhancing customer service capabilities[66]. - The company is focusing on a modern logistics distribution model to support national expansion and regional deepening[63]. - The company is actively exploring the DTP business model and is developing a professional management system to enhance patient management and prescription services[60]. - The company is preparing for a new round of equity incentive plans and employee stock ownership plans to support future growth[69]. Member Engagement and Community Activities - The number of active members exceeded 25 million by September 30, 2023, with member consumption accounting for over 70% of total sales and a retention rate of 78%[53]. - The company conducted 994 health community activities across 40 regions, enhancing brand awareness and member engagement[55].